All In Biotech

Drug Trial Radar · NCT02570321

Cross-linking for Corneal Ulcers Treatment Trial

Last checked: Nov 19, 2026Latest source record: Jun 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 147 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

147

Actual

Start

Nov 2015

Primary completion

Jun 18, 2018

Study completion Mar 19, 2019

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Aravind Eye Hospitals, India
First posted
Oct 7, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to determine if patients randomized to corneal collagen cross-linking plus medical therapy will have a lower prevalence of positive bacterial or fungal cultures immediately after the procedure than patients who received medical therapy alone. The secondary purpose of this study is to determine if patients randomized to corneal collagen cross-linking will have a better visual acuity at 3 and 12 months than patients who receive medical therapy alone.

Conditions

  • Corneal Ulcer
  • Infectious Keratitis
  • Bacterial Ulcer
  • Fungal Ulcer

Interventions

  • Corneal Cross-linkingProcedure

    For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis.

  • Anti Fungal DrugDrug

    Topical Amphotericin B vs Topical Natamycin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Microbiological Cure on Repeat CultureTime frame: 4 to 24 hours after enrollment

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Proctor Foundation, UCSF

    San Francisco, California

  • Aravind Eye Hospitals

    Madurai, Tamil Nadu, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.